Latest Period
Q4 2025
Security Snapshot
Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) Institutional Ownership
CUSIP: 28036F105
13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026
Institutions Reporting
197
Shares (Excl. Options)
121,822,383
Price
$24.82
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- EWTX on Nasdaq
- Shares outstanding
- 109,183,673
- Price per share
- $31.50
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 121,822,383
- Total reported value
- $3,022,521,297
- % of total 13F portfolios
- 0.01%
- Share change
- +10,277,553
- Value change
- +$263,739,340
- Number of holders
- 197
- Price from insider filings
- $31.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 28036F105.
- 197 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 197 to 31 between Q4 2025 and Q1 2026.
- Reported value moved from $3,022,521,297 to $45,201,264.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 197 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 28036F105?
CUSIP 28036F105 identifies EWTX - Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28036F105:
Significant Owners of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | $234,894,152 | 15,252,867 | ORBIMED ADVISORS LLC | 09 May 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $169,149,248 | 10,428,437 | RA Capital Management, L.P. | 30 Sep 2025 | |||
| BAKER BROS. ADVISORS LP | 6.9% | $95,196,398 | 7,305,940 | Baker Bros. Advisors LP | 30 Jun 2025 | |||
| Paradigm Biocapital Advisors LP | 6.2% | +24% | $161,371,651 | +$44,462,272 | 6,541,210 | +38% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| BlackRock, Inc. | 5.5% | $76,363,411 | 5,824,866 | BlackRock, Inc. | 30 Jun 2025 | |||
| Novo Holdings A/S | 4.9% | $168,525,535 | 5,350,000 | Novo Holdings A/S | 23 Apr 2026 | |||
| JANUS HENDERSON GROUP PLC | 4.7% | -10% | $80,764,749 | -$8,499,572 | 4,979,331 | -9.5% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| PERCEPTIVE ADVISORS LLC | 4.4% | -28% | $60,458,535 | -$22,875,429 | 4,639,949 | -27% | Perceptive Advisors LLC | 30 Jun 2025 |
As of 31 Dec 2025, 197 institutional investors reported holding 121,822,383 shares of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX). This represents 112% of the company’s total 109,183,673 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) together control 93% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | 15,518,492 | 0% | 8.2% | $385,091,379 |
| RA CAPITAL MANAGEMENT, L.P. | 9.6% | 10,428,437 | 0% | 2.7% | $258,781,664 |
| BlackRock, Inc. | 6.1% | 6,630,576 | +4.4% | 0% | $164,537,741 |
| BAKER BROS. ADVISORS LP | 6% | 6,575,940 | -10% | 0.96% | $163,181,951 |
| Paradigm Biocapital Advisors LP | 6% | 6,541,210 | +6% | 4.3% | $162,320,126 |
| NOVO HOLDINGS A/S | 4.9% | 5,350,000 | 0% | 10% | $132,760,250 |
| BRAIDWELL LP | 4.8% | 5,210,831 | 0% | 4.1% | $129,306,771 |
| VANGUARD GROUP INC | 4.5% | 4,871,624 | +1.4% | 0% | $120,889,349 |
| JANUS HENDERSON GROUP PLC | 4.2% | 4,566,850 | -8.3% | 0.05% | $113,326,384 |
| Siren, L.L.C. | 4.1% | 4,529,990 | +16% | 3.4% | $112,411,702 |
| PERCEPTIVE ADVISORS LLC | 4.1% | 4,457,974 | +17% | 2% | $110,624,625 |
| Driehaus Capital Management LLC | 3.8% | 4,191,193 | +88% | 0.71% | $104,004,458 |
| Cormorant Asset Management, LP | 3% | 3,285,000 | -18% | 4.6% | $81,517,275 |
| MORGAN STANLEY | 2.7% | 2,910,881 | +235% | 0% | $72,233,511 |
| UBS Group AG | 1.9% | 2,117,073 | +1755% | 0.01% | $52,535,166 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,746,222 | +1.7% | 0% | $43,340,399 |
| STATE STREET CORP | 1.6% | 1,717,343 | +1% | 0% | $42,615,867 |
| MPM BIOIMPACT LLC | 1.5% | 1,655,256 | -3.8% | 4.7% | $41,075,178 |
| First Light Asset Management, LLC | 1.4% | 1,573,701 | +11% | 3% | $39,051,392 |
| Bellevue Group AG | 1.4% | 1,528,518 | -45% | 0.72% | $37,930,174 |
| Integral Health Asset Management, LLC | 1.4% | 1,500,000 | 0% | 1.9% | $37,222,500 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,474,797 | +359% | 0% | $36,597,088 |
| DIMENSIONAL FUND ADVISORS LP | 1.1% | 1,213,657 | +2.6% | 0.01% | $30,114,975 |
| AMERICAN CENTURY COMPANIES INC | 1.1% | 1,186,467 | +8.3% | 0.01% | $29,442,210 |
| ALLIANCEBERNSTEIN L.P. | 0.95% | 1,036,170 | +1241% | 0.01% | $25,712,559 |
Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,434,922 | $45,201,264 | +$7,426,084 | $31.50 | 31 |
| 2025 Q4 | 121,822,383 | $3,022,521,297 | +$263,739,340 | $24.82 | 197 |
| 2025 Q3 | 111,964,035 | $1,816,272,411 | -$102,066,033 | $16.22 | 172 |
| 2025 Q2 | 118,737,861 | $1,557,153,070 | +$135,315,946 | $13.11 | 177 |
| 2025 Q1 | 105,289,941 | $2,320,227,206 | +$130,326,516 | $22.00 | 190 |
| 2024 Q4 | 98,918,436 | $2,640,722,866 | -$78,891,260 | $26.70 | 197 |
| 2024 Q3 | 101,289,495 | $2,703,865,523 | -$12,073,061 | $26.69 | 174 |
| 2024 Q2 | 101,617,706 | $1,830,101,707 | +$179,027,088 | $18.01 | 138 |
| 2024 Q1 | 91,602,360 | $1,670,777,013 | +$311,144,088 | $18.24 | 126 |
| 2023 Q4 | 79,647,397 | $871,350,413 | +$122,344,417 | $10.94 | 115 |
| 2023 Q3 | 68,438,296 | $392,172,292 | -$8,215,044 | $5.73 | 84 |
| 2023 Q2 | 69,494,963 | $538,802,876 | +$23,832,932 | $7.75 | 94 |
| 2023 Q1 | 66,455,672 | $443,090,314 | -$748,812 | $6.67 | 85 |
| 2022 Q4 | 66,466,915 | $594,208,237 | +$17,736,112 | $8.94 | 90 |
| 2022 Q3 | 64,390,889 | $633,608,275 | +$132,537,303 | $9.84 | 92 |
| 2022 Q2 | 50,965,041 | $405,682,841 | -$30,249,561 | $7.96 | 76 |
| 2022 Q1 | 53,964,373 | $523,513,727 | +$33,997,944 | $9.70 | 71 |
| 2021 Q4 | 50,239,434 | $767,640,710 | +$33,441,771 | $15.28 | 56 |
| 2021 Q3 | 48,038,152 | $795,758,000 | +$3,108,242 | $16.60 | 47 |
| 2021 Q2 | 46,323,514 | $984,550,000 | +$40,348,386 | $21.33 | 45 |
| 2021 Q1 | 45,681,359 | $1,477,378,000 | +$1,477,377,994 | $32.50 | 31 |